The ASSIST study will evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
You will take atrasentan or the placebo as a tablet by mouth while also taking an SGLT2i. At each visit, you will meet with a member of the study team and fill out questionnaires. At some visits you will be asked for blood and urine samples.
Clinical or Medical
Kidneys and Liver